Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanCogenics Invited to Present Novel Technology for the Targeted Delivery of Cancer Therapeutics at BioNanoMed 2013, the Fourth Annual International Conference

Abstract:
Officials at NanCogenics, Inc. announced today that Co-Founder Dr. Jim Klostergaard has been invited to present at the upcoming BioNanoMed 4th International Conference on Nanotechnology, Medicine and Biology, to be held March 13-15, in Krems, Austria. Dr. Klostergaard will speak about a paper titled "A Cancer Treatment Modality Based on the Tumor-Specific Localization of Cancer Therapeutics", which will discuss the application of the company's tumor targeting platform as a clinical procedure.

NanCogenics Invited to Present Novel Technology for the Targeted Delivery of Cancer Therapeutics at BioNanoMed 2013, the Fourth Annual International Conference

Houston, TX | Posted on March 6th, 2013

This prestigious three day congress will bring together academia, industry, governmental and non-governmental institutions to discuss current, emerging and future trends of the converging fields of Nanotechnology, Biotechnology and Medicine. The theme for BioNanoMed 2013 is Nanotechnology Enables Personalized Medicine which focuses on current and developing efforts to bring an individualized approach to cancer therapy.

The NanCogenics technology platform, as envisioned by Co-Founders, Dr. Klostergaard, Professor of Molecular and Cellular Oncology at the University of Texas M D Anderson Cancer Center (Houston, TX), and Charles Seeney, Managing Director of NewTech Development (Edmond, OK), enables the emerging trend to personalized medicine. The nanotechnology-based platform is based on designed therapeutic nano prodrug constructs that respond to external magnetic forces in targeting tumor sites, generating effective anti-tumor results without harm to normal tissue or organs, thereby substantially reducing the feared side effects and complications often attributed to chemotherapy. The Co-Founders believe that the advancement of this platform to the clinic will lead to significant improvements, not only in cancer chemotherapy, but also as a means of targeting a range of new cancer therapeutics now under development.

The Company's newly recruited President and CEO, states that "this conference provides a significant first step in our efforts to raise the awareness of the potential of magnetic localization, and the impact NanCogenics can have in the emerging field of nanomedicine". He further states that the Company is moving forward with funding mechanisms to support business objectives and anticipated future FDA IND filings.

####

About NanCogenics, Inc.
Overall, NanCogenics sees itself as a resource for enhanced and improved therapeutic performance, with more drug penetration occurring at the target site and less to normal tissue. The capacity to localize cytotoxic drugs in high concentrations at the tumor site will lead to more effective treatment regimens, greater patient compliance to therapy and improved outcomes, such as patient quality of life and survival rates.

Safe Harbor Statement

Certain statement included in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of products and services, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. The company's expectations regarding future revenues are dependent upon the ability to develop and supply products and services that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions are generally considered forward-looking statements. These statements reflect current expectations.

For more information, please click here

Contacts:
NCGI
Charles Seeney

Ph: 855.842.6771

Copyright © NanCogenics, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Atomic imperfections move quantum communication network closer to reality June 25th, 2017

Research accelerates quest for quicker, longer-lasting electronics: UC Riverside-led research makes topological insulators magnetic well above room temperatures June 25th, 2017

U.S. Air Force Research Lab Taps IBM to Build Brain-Inspired AI Supercomputing System: Equal to 64 million neurons, new neurosynaptic supercomputing system will power complex AI tasks at unprecedented speed and energy efficiency June 23rd, 2017

Rice U. chemists create 3-D printed graphene foam June 22nd, 2017

Nanomedicine

Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017

Learning with light: New system allows optical ďdeep learningĒ: Neural networks could be implemented more quickly using new photonic technology June 12th, 2017

Mussels add muscle to biocompatible fibers: Rice University chemists develop hydrogel strings using compound found in sea creatures June 9th, 2017

Making vessels leaky on demand could aid drug delivery:Rice University scientists use magnets and nanoparticles to open, close gaps in blood vessels June 8th, 2017

Announcements

Atomic imperfections move quantum communication network closer to reality June 25th, 2017

Research accelerates quest for quicker, longer-lasting electronics: UC Riverside-led research makes topological insulators magnetic well above room temperatures June 25th, 2017

U.S. Air Force Research Lab Taps IBM to Build Brain-Inspired AI Supercomputing System: Equal to 64 million neurons, new neurosynaptic supercomputing system will power complex AI tasks at unprecedented speed and energy efficiency June 23rd, 2017

Rice U. chemists create 3-D printed graphene foam June 22nd, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Events/Classes

Letiís Autonomous-Vehicle System Embedded in Infineonís AURIX Platform: Letiís Low-Power, Multi-Sensor System that Transforms Distance Data into Clear Information About the Driving Environment Will Be Demonstrated at ITS Meeting in Strasbourg, June 19-22 June 20th, 2017

Nanomechanics to Host High-Speed Nanoindentation Webinar June 21: Leading nanomechanical technology provider will host educational webinar focused on high-speed nanoindentation and mechanical properties mapping June 12th, 2017

Nanobiotix's promising data from Phase I/II head and neck cancer trial presented at ASCO June 5th, 2017

Nanomechanics, Inc. to Exhibit at the SEM Conference: Nanoindentation experts will attend and exhibit their instruments at the Conference and Exposition on Experimental and Applied Mechanics in Indianapolis May 25th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project